Omega-3 in SLE: A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

Kayode J. Bello, Hong Fang, Parastoo Fazeli, Waleed Bolad, Mary Corretti, Laurence S. Magder, Michelle Petri

Research output: Contribution to journalArticle

Abstract

Accelerated atherosclerosis remains a major cause of death in late systemic lupus erythematosus (SLE). Omega-3 has been reported to have benefit for endothelial dysfunction, one of the earliest stages of atherosclerosis, and to reduce disease activity in SLE. We performed a randomized, double-blind placebo-controlled trial to examine the effect of Omega-3 on endothelial function, disease activity, inflammatory markers and lipids in SLE. SLE patients (n = 85, mean age 47, 55 % Caucasian, 38 % African-American, 94 % female) were randomly assigned to 3 g of Omega-3 (Lovaza, GSK) versus placebo for 12 weeks. Endothelial function was measured at baseline and at 12 weeks using flow-mediated dilation, calculated using high-resolution B-mode ultrasound of the brachial artery diameter in response to vasoactive stimuli (hyperemia). Disease activity was measured using the physician global assessment and SELENA-SLEDAI score. Inflammatory markers (sICAM-1, sVCAM-1, IL-6) and fasting lipid profile were done at baseline and 12-week follow-up. There was no difference between the treatment groups with respect to changes in flow-mediated dilation parameters or disease activity. An average increase in LDL cholesterol of 3.11 mg/dL (±21.99) was found with Omega-3 versus a decrease of 1.87 mg/dL (±18.29) with placebo (p = 0.0266). In this trial, Omega-3 did not improve endothelial function, disease activity, nor reduce inflammatory markers in SLE. Longer trials might be required if there are delayed clinical effects. There was evidence that Omega-3 may increase LDL cholesterol, but not the LDL/HDL ratio.

Original languageEnglish (US)
Pages (from-to)2789-2796
Number of pages8
JournalRheumatology International
Volume33
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Systemic Lupus Erythematosus
Randomized Controlled Trials
Placebos
LDL Cholesterol
Dilatation
Atherosclerosis
Glycogen Synthase Kinase 3
Lipids
Brachial Artery
Hyperemia
African Americans
Cause of Death
Interleukin-6
Fasting
Physicians
Therapeutics

Keywords

  • Flow-mediated dilation
  • LDL cholesterol
  • Omega-3
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Omega-3 in SLE : A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. / Bello, Kayode J.; Fang, Hong; Fazeli, Parastoo; Bolad, Waleed; Corretti, Mary; Magder, Laurence S.; Petri, Michelle.

In: Rheumatology International, Vol. 33, No. 11, 11.2013, p. 2789-2796.

Research output: Contribution to journalArticle

@article{b68eb627ea204625a7f2c7637be6d206,
title = "Omega-3 in SLE: A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus",
abstract = "Accelerated atherosclerosis remains a major cause of death in late systemic lupus erythematosus (SLE). Omega-3 has been reported to have benefit for endothelial dysfunction, one of the earliest stages of atherosclerosis, and to reduce disease activity in SLE. We performed a randomized, double-blind placebo-controlled trial to examine the effect of Omega-3 on endothelial function, disease activity, inflammatory markers and lipids in SLE. SLE patients (n = 85, mean age 47, 55 {\%} Caucasian, 38 {\%} African-American, 94 {\%} female) were randomly assigned to 3 g of Omega-3 (Lovaza, GSK) versus placebo for 12 weeks. Endothelial function was measured at baseline and at 12 weeks using flow-mediated dilation, calculated using high-resolution B-mode ultrasound of the brachial artery diameter in response to vasoactive stimuli (hyperemia). Disease activity was measured using the physician global assessment and SELENA-SLEDAI score. Inflammatory markers (sICAM-1, sVCAM-1, IL-6) and fasting lipid profile were done at baseline and 12-week follow-up. There was no difference between the treatment groups with respect to changes in flow-mediated dilation parameters or disease activity. An average increase in LDL cholesterol of 3.11 mg/dL (±21.99) was found with Omega-3 versus a decrease of 1.87 mg/dL (±18.29) with placebo (p = 0.0266). In this trial, Omega-3 did not improve endothelial function, disease activity, nor reduce inflammatory markers in SLE. Longer trials might be required if there are delayed clinical effects. There was evidence that Omega-3 may increase LDL cholesterol, but not the LDL/HDL ratio.",
keywords = "Flow-mediated dilation, LDL cholesterol, Omega-3, Systemic lupus erythematosus",
author = "Bello, {Kayode J.} and Hong Fang and Parastoo Fazeli and Waleed Bolad and Mary Corretti and Magder, {Laurence S.} and Michelle Petri",
year = "2013",
month = "11",
doi = "10.1007/s00296-013-2811-3",
language = "English (US)",
volume = "33",
pages = "2789--2796",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Omega-3 in SLE

T2 - A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

AU - Bello, Kayode J.

AU - Fang, Hong

AU - Fazeli, Parastoo

AU - Bolad, Waleed

AU - Corretti, Mary

AU - Magder, Laurence S.

AU - Petri, Michelle

PY - 2013/11

Y1 - 2013/11

N2 - Accelerated atherosclerosis remains a major cause of death in late systemic lupus erythematosus (SLE). Omega-3 has been reported to have benefit for endothelial dysfunction, one of the earliest stages of atherosclerosis, and to reduce disease activity in SLE. We performed a randomized, double-blind placebo-controlled trial to examine the effect of Omega-3 on endothelial function, disease activity, inflammatory markers and lipids in SLE. SLE patients (n = 85, mean age 47, 55 % Caucasian, 38 % African-American, 94 % female) were randomly assigned to 3 g of Omega-3 (Lovaza, GSK) versus placebo for 12 weeks. Endothelial function was measured at baseline and at 12 weeks using flow-mediated dilation, calculated using high-resolution B-mode ultrasound of the brachial artery diameter in response to vasoactive stimuli (hyperemia). Disease activity was measured using the physician global assessment and SELENA-SLEDAI score. Inflammatory markers (sICAM-1, sVCAM-1, IL-6) and fasting lipid profile were done at baseline and 12-week follow-up. There was no difference between the treatment groups with respect to changes in flow-mediated dilation parameters or disease activity. An average increase in LDL cholesterol of 3.11 mg/dL (±21.99) was found with Omega-3 versus a decrease of 1.87 mg/dL (±18.29) with placebo (p = 0.0266). In this trial, Omega-3 did not improve endothelial function, disease activity, nor reduce inflammatory markers in SLE. Longer trials might be required if there are delayed clinical effects. There was evidence that Omega-3 may increase LDL cholesterol, but not the LDL/HDL ratio.

AB - Accelerated atherosclerosis remains a major cause of death in late systemic lupus erythematosus (SLE). Omega-3 has been reported to have benefit for endothelial dysfunction, one of the earliest stages of atherosclerosis, and to reduce disease activity in SLE. We performed a randomized, double-blind placebo-controlled trial to examine the effect of Omega-3 on endothelial function, disease activity, inflammatory markers and lipids in SLE. SLE patients (n = 85, mean age 47, 55 % Caucasian, 38 % African-American, 94 % female) were randomly assigned to 3 g of Omega-3 (Lovaza, GSK) versus placebo for 12 weeks. Endothelial function was measured at baseline and at 12 weeks using flow-mediated dilation, calculated using high-resolution B-mode ultrasound of the brachial artery diameter in response to vasoactive stimuli (hyperemia). Disease activity was measured using the physician global assessment and SELENA-SLEDAI score. Inflammatory markers (sICAM-1, sVCAM-1, IL-6) and fasting lipid profile were done at baseline and 12-week follow-up. There was no difference between the treatment groups with respect to changes in flow-mediated dilation parameters or disease activity. An average increase in LDL cholesterol of 3.11 mg/dL (±21.99) was found with Omega-3 versus a decrease of 1.87 mg/dL (±18.29) with placebo (p = 0.0266). In this trial, Omega-3 did not improve endothelial function, disease activity, nor reduce inflammatory markers in SLE. Longer trials might be required if there are delayed clinical effects. There was evidence that Omega-3 may increase LDL cholesterol, but not the LDL/HDL ratio.

KW - Flow-mediated dilation

KW - LDL cholesterol

KW - Omega-3

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84886721423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886721423&partnerID=8YFLogxK

U2 - 10.1007/s00296-013-2811-3

DO - 10.1007/s00296-013-2811-3

M3 - Article

C2 - 23817872

AN - SCOPUS:84886721423

VL - 33

SP - 2789

EP - 2796

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 11

ER -